Abstract
Southern Africa is burdened with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (M.tuberculosis) infections as well as conditions of iron (Fe) overload. Highly Active Antiretroviral Therapy (HAART) is used to treat HIV-infection, many drugs exist for the treatment of tuberculosis (new solutions are also being sought because of the existence of multi drug resistant strains of M.tuberculosis) and Fe chelators are commonly used to treat Fe overload. Chelators have also been shown to inhibit the multiplication of numerous microorganisms and hence there are publications suggesting a role for chelators like desferrioxamine (DFO) in the dual treatment of microorganism infection and excess iron. Excess iron fuels pathogen survival which in turn lowers host cell functionality (manifested as altered proliferation, cytokine secretion, etc); withholding iron (via a chelator) reverses the process, even more so when the cells are chelated for longer periods of time. Chelation with DFO is reviewed here by commenting on its immunomodulatory effect.
Keywords: Desferrioxamine, HIV, M.tuberculosis, iron, immunomodulatory, immune restoration
Current Pharmaceutical Design
Title: Desferrioxamine as Immunomodulatory Agent During Microorganism Infection
Volume: 15 Issue: 11
Author(s): A. Williams and D. Meyer
Affiliation:
Keywords: Desferrioxamine, HIV, M.tuberculosis, iron, immunomodulatory, immune restoration
Abstract: Southern Africa is burdened with Human Immunodeficiency Virus (HIV) and Mycobacterium tuberculosis (M.tuberculosis) infections as well as conditions of iron (Fe) overload. Highly Active Antiretroviral Therapy (HAART) is used to treat HIV-infection, many drugs exist for the treatment of tuberculosis (new solutions are also being sought because of the existence of multi drug resistant strains of M.tuberculosis) and Fe chelators are commonly used to treat Fe overload. Chelators have also been shown to inhibit the multiplication of numerous microorganisms and hence there are publications suggesting a role for chelators like desferrioxamine (DFO) in the dual treatment of microorganism infection and excess iron. Excess iron fuels pathogen survival which in turn lowers host cell functionality (manifested as altered proliferation, cytokine secretion, etc); withholding iron (via a chelator) reverses the process, even more so when the cells are chelated for longer periods of time. Chelation with DFO is reviewed here by commenting on its immunomodulatory effect.
Export Options
About this article
Cite this article as:
Williams A. and Meyer D., Desferrioxamine as Immunomodulatory Agent During Microorganism Infection, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846801
DOI https://dx.doi.org/10.2174/138161209787846801 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Short-Term Transfer of Knowledge Assessment in the Military International HIV Training Program (MIHTP)
Current HIV Research Mother-to-Child Transmission of HIV Infection and its Prevention
Current HIV Research Disruption of Circadian Rhythms in Critical Illness - A Role of Hyperoxia-Induced Lung Injury
Current Pharmaceutical Design Synthesis of 3-(7-Methylbenzo[d]oxazol-4-yl) Butanoic Acid: A Precursor of (+)-seco-Pseudopteroxazole and (+)-Pseudopteroxazole
Letters in Organic Chemistry Sepsis: Links between Pathogen Sensing and Organ Damage
Current Pharmaceutical Design Metal-Based Antimicrobial Protease Inhibitors
Current Medicinal Chemistry Current Therapeutics, Their Problems and Thiol Metabolism as Potential Drug Targets in Leishmaniasis
Current Drug Metabolism Mangrove Plants as a Source of Bioactive Compounds: A Review
The Natural Products Journal A Technological Update of Molecular Diagnostics for Infectious Diseases
Infectious Disorders - Drug Targets Can Probiotics Cure Inflammatory Bowel Diseases?
Current Pharmaceutical Design Preliminary Studies on Ligand-based Design and Evaluation of New Mycobacterial ATP Synthase Inhibitors
Current Drug Therapy p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis
Mini-Reviews in Medicinal Chemistry Targeting Bacterial Metalloenzymes: A New Strategy for the Development of Anti-Infective Agents
Anti-Infective Agents in Medicinal Chemistry New Bioactive Metabolites from the Marine-derived Fungi Aspergillus
Mini-Reviews in Medicinal Chemistry CRISPeering: Bioengineering the Host Cells through CRISPRCas9 Genome Editing System as the Next-generation of Cell Factories
Recent Patents on Biotechnology New Insights in Design and Development of Antitubercular Drugs
Current Bioactive Compounds Synthesis and Antitubercular Screening of Some Novel 4H-1,4- Benzothiazines and their Sulfones Under Environment Benign Solvent Free Conditions as Future Anti-Tubercular Agents
Combinatorial Chemistry & High Throughput Screening Virus-Associated Vasculitides
Current Immunology Reviews (Discontinued) Blood-brain Barrier Drug Discovery for Central Nervous System Infections
Current Drug Targets - Infectious Disorders Potential Inhibitor of Adenylyl Sulfate Reductase Isolated from Desulfovibrio desulfuricans with PU/PU-Ag to Control Pitting Corrosion of Oil Tanks and Pipelines
Current Enzyme Inhibition